Harmony Biosciences
HRMY
323 hedge funds and large institutions have $1.87B invested in Harmony Biosciences in 2025 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 122 increasing their positions, 110 reducing their positions, and 29 closing their positions.
100% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 29
55% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $7.67M
43% more capital invested
Capital invested by funds: $1.3B → $1.87B (+$562M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 110
9% more funds holding
Funds holding: 296 → 323 (+27)
4.24% more ownership
Funds ownership: 82.38% → 86.62% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$30.9M |
| 2 |
AC
Armistice Capital
New York
|
+$16.4M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$15.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
Valor Management
Chicago,
Illinois
|
-$37.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.33M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$8.41M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.77M |
HRMY Hedge Fund Activity: Q4 2025 in Review
323 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2025, worth a combined $1.87B — up 43% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new HRMY positions and 29 closed out — a net gain of 29 holders — while 122 added to existing stakes and 110 trimmed.
The largest buyer was SG Americas Securities, adding an estimated $30.9M. The largest seller was Valor Management, cutting an estimated $37.8M.
- 323 institutional investors held Harmony Biosciences (HRMY) as of Q4 2025, up from 296 in Q3 2025.
- Funds reported $1.87B of Harmony Biosciences stock for Q4 2025, up 43% quarter-over-quarter.
- 58 funds opened new Harmony Biosciences positions in Q4 2025 and 29 closed out, a net change of +29 holders.
- The largest Harmony Biosciences buyer in Q4 2025 was SG Americas Securities, an estimated $30.9M added.
- The largest Harmony Biosciences seller in Q4 2025 was Valor Management, an estimated $37.8M sold.
Based on aggregated 13F filings for Q4 2025.